Literature DB >> 33251569

Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian Population: A Cross-Sectional Study.

Helia Alavifard1, Nasrin Mirzaei1, Abbas Yadegar2, Kaveh Baghaei3, Sinéad Marian Smith4, Amir Sadeghi3, Mohammad Reza Zali3.   

Abstract

Antibiotic resistance has brought into question the efficiency of clarithromycin which is a vital component of eradication therapy for Helicobacter pylori infection. The point mutations within the 23S rRNA sequence of H. pylori isolates which contribute to clarithromycin resistance have yet to be fully characterized. This study was aimed to detect clarithromycin resistance-associated mutations and assess the prevalence of key virulence factors of H. pylori among Iranian patients. Amplification of 16S rRNA and glmM genes were done to identify H. pylori. Minimal inhibitory concentration (MIC) of clarithromycin in 82 H. pylori clinical isolates was determined by agar dilution method. Subsequently, various virulence markers including cagA, vacA, sabA, babA, and dupA of H. pylori were identified by PCR. PCR-sequencing was applied to detect point mutations in the 23S rRNA gene. Based on MIC values, 43.9% of H. pylori isolates showed resistance to clarithromycin. The babA and cagA genes were detected in 92.7% and 82.9% of isolates, assigned to be higher than other virulence factors. No significant relationship was found between the H. pylori virulence genotypes and clarithromycin susceptibility (P > 0.05). Analyzing the 23S rRNA sequences revealed A2143G (4/48, 8.3%) and A2142G (3/48, 6.2%) as the most prevalent mutations in clarithromycin-resistant isolates. Additionally, several novel mutations including G2220T, C2248T, A2624C, G2287A, T2188C, G2710C, C2248T, G2269A, and G2224T were also detected among either resistant or susceptible isolates. Our findings revealed the presence of several point mutations in the 23S rRNA gene of H. pylori isolates which may be associated with resistance to clarithromycin.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33251569     DOI: 10.1007/s00284-020-02295-7

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  36 in total

1.  Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.

Authors:  Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers
Journal:  Gut       Date:  2012-05       Impact factor: 23.059

2.  Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

Authors:  P Malfertheiner; F Megraud; C A O'Morain; J P Gisbert; E J Kuipers; A T Axon; F Bazzoli; A Gasbarrini; J Atherton; D Y Graham; R Hunt; P Moayyedi; T Rokkas; M Rugge; M Selgrad; S Suerbaum; K Sugano; E M El-Omar
Journal:  Gut       Date:  2016-10-05       Impact factor: 23.059

3.  High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain.

Authors:  Sonia Agudo; Guillermo Pérez-Pérez; Teresa Alarcón; Manuel López-Brea
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

4.  Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.

Authors:  Ju Yup Lee; Nayoung Kim; Min Soo Kim; Yoon Jin Choi; Jung Won Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung
Journal:  Dig Dis Sci       Date:  2014-03-06       Impact factor: 3.199

5.  Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.

Authors:  Chao-Hung Kuo; Huang-Ming Hu; Fu-Chen Kuo; Ping-I Hsu; Angela Chen; Fang-Jung Yu; Pei-Yun Tsai; I-Chen Wu; Sheng-Wen Wang; Chia-Jung Li; Bi-Chuang Weng; Lin-Li Chang; Chang-Ming Jan; Wen-Ming Wang; Deng-Chyang Wu
Journal:  J Antimicrob Chemother       Date:  2009-02-26       Impact factor: 5.790

6.  PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies.

Authors:  Bryan H Schmitt; Maryann Regner; Kathy A Mangold; Richard B Thomson; Karen L Kaul
Journal:  Mod Pathol       Date:  2013-04-12       Impact factor: 7.842

Review 7.  DRUG RESISTANCE IN HELICOBACTER PYLORI.

Authors:  Júlia Silveira Vianna; Ivy Bastos Ramis; Daniela Fernandes Ramos; Andrea VON Groll; Pedro Eduardo Almeida da Silva
Journal:  Arq Gastroenterol       Date:  2016 Oct-Dec

Review 8.  Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection.

Authors:  Nazlı Arslan; Özlem Yılmaz; Ebru Demiray-Gürbüz
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

Review 9.  Helicobacter pylori BabA in adaptation for gastric colonization.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  World J Gastroenterol       Date:  2017-06-21       Impact factor: 5.742

10.  Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible Helicobacter pylori strains with A2143G of 23S rRNA gene.

Authors:  Jiaoe Chen; Liping Ye; Liangmin Jin; Xuehua Xu; Peisong Xu; Xianjun Wang; Hongzhang Li
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-03-22       Impact factor: 3.944

View more
  2 in total

1.  Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial.

Authors:  Bader Faiyaz Zuberi; Faiza Sadaqat Ali; Tazeen Rasheed; Nimrah Bader; Sana Muhammad Hussain; Anoshia Saleem
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

2.  Persister cells as a possible cause of antibiotic therapy failure in Helicobacter pylori.

Authors:  Parvin Bahmaninejad; Sobhan Ghafourian; Mina Mahmoudi; Abbas Maleki; Nourkhoda Sadeghifard; Behzad Badakhsh
Journal:  JGH Open       Date:  2021-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.